Differentiating the Fourth-Generation Fluoroquinolones From: Ophthalmology Times | Date: March 15, 2004| Author: Roberts, Calvin W | Copyright Advanstar Communications, Inc. Mar 15, 2004. Provided by ProQuest LLC.Copyright information

Published reports of experimental Laboratory investigations involving bacterial isolates from endophthalmitis1 and keratitis2 concur that both fourth-generation fluoroquinolones gatifloxacin and moxifloxacin are more potent than the second- and third-generation fluoroquinolones for gram-positive bacteria. These published data also consistently indicate that the fourth-generation agents offer advantages over ear lier generations for coverage of resistant organisms such as Staphylococcus aureus...

Related newspaper, magazine, and journal articles from HighBeam Research

	Newer fluoroquinolones preferred antimicrobial prophylaxis Ophthalmology Times ; Comparison studies Patients undergoing excimer laser refractive procedures can be assured of broad-spectrum coverage Reviewed by Daniel S. Durrie, MD, and William Trattler, MD; The fourth-generation fluoroquinolones gatifloxacin 0.3% (Zymar, Allergan) and moxifloxacin 0.5% (Vigamox, Alcon
	Proper use of antibiotics essential for good outcomes Ophthalmology Times ; Refractive surgery Proper use of antibiotics essential for good outcomes Reviewed by Eduardo C. Alfonso, MD, Deepinder K. Dhaliwal, MD, Edward J. Holland, MD, Samuel Masket, MD, and Michael B. Raizman, MD Antibiotic resistance is a growing challenge, especially in ophthalmic surgery, and clinicians
	Oral moxifloxacin might be adjunct in endophthalmitis Ophthalmology Times ; Intravitreal penetration Fluoroquinolone shown to have significant vitreous penetration, according to retina fellow Reviewed by Jeffrey J. Fuller, MD Montral-Oral moxifloxacin (Avelox, Bayer) can penetrate into the vitreous at a level that can kill most common pathogens in the eye. This drug, a
	Fourth-generation fluoroquinolones offer improved coverage Ophthalmology Times ; Increased potency Fort Lauderdale, FL-The investigational fourth-generation fluoroquinolones moxifloxacin and gatifloxacin show promising potential for providing broad-- spectrum coverage against important gram-negative and gram-positive ocular pathogens, according to results of in vitro
	Kill-curve studies provide important data Ophthalmology Times ; Antimicrobial activity Research compares two fourth-generation fluoroquinolones, finds gatifloxacin superior Reviewed by Mark McDermott, MT, MD San Diego-Gatifloxacin 0.3% ophthalmic solution (Zymar, Allergan) reduces viability of staphylococcal strains more rapidly and more completely than

See all results.